Last reviewed · How we verify
NCT07401420: LST-Ped-Int
Life Sustaining Treatments in Critically Ill Children
trial testing There is no intervention in Critical Illness in 30 participants. Not yet recruiting.
31 December 2027
Quick facts
| Lead sponsor | Göteborg University |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 1 February 2026 |
| Primary completion | 31 December 2027 |
| Estimated completion | 31 December 2027 |
Drugs / interventions tested
- There is no intervention — full drug profile →
Conditions studied
- Critical Illness — all drugs for Critical Illness →
- Ethics — all drugs for Ethics →
- End of Life Care — all drugs for End of Life Care →
Sponsor
Göteborg University
Who can join
18 and older, any sex, with Critical Illness or Ethics. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Summary of the Research on Withdrawing and Withholding Life-Sustaining Treatment for Critically Ill Children Background Medical treatments require regular evaluation to ensure they align with the patient's best interests, particularly in intensive care where quality of life is often compromised. In the context of critically ill children, the challenge increases as patients may not be fully conscious or capable of expressing their needs and preferences. While intensive care can extend life, end-of-life situations necessitate careful consideration to avoid providing futile treatments that do not benefit the patient. Decision-Making Complexity Identifying when further treatment is beneficial poses significant challenges, influenced by various factors including the wishes of the patient and guardians. Previous studies indicate variability among healthcare providers in treatment decisions, often stemming from personal experiences and emotional responses. However, comparable research focusing on critically ill children in Nordic contexts remains scarce. Medical decisions often require balancing potential benefits against the risks of extended suffering or loss of valuable time at the end of life. A previous survey on end-of-life care in Europe indicated similar attitudes across regions but highlighted the need for cultural considerations. Sweden's distinct social and cultural values, characterized by individualism and secularism, may influence practices surrounding life-sustaining treatment. Research Aims This research aims to investigate the factors affecting decision-making regarding the withdrawal and withholding of life-sustaining treatments for critically ill children in Swedish and Nordic intensive care units (ICUs). It will examine practitioners' experiences, attitudes, and the relative impact of children's autonomy in these decisions, excluding neonatal care. Key scientific questions focus on Physicians' attitudes and challenges regarding treatment withdrawal. Methodology Semi-structured interviews in multiple ICUs to explore ethical dilemmas faced by physicians.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07401420
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of There is no intervention
Trials testing the same drug.
- NCT06343675 — Systematic Health-promoting Work Environment Management in Dentistry · completed
- NCT06517238 — A New Digital Communication Tool Between Dentist and Orthodontist to Improve Dental Prevention · recruiting
- NCT06301217 — Are Axioscapular Muscles Activity and Cervical Curvature Associated With Disability in Neck Pain · unknown
- NCT05981599 — Epidemiological, Clinical and Biological Caracteristics of Patients Presenting With Invasive Meningococcal Disease · unknown
- NCT05233319 — mCVI Confirmatory Clinical Study: Algorithm Verification With Healthy Volunteers · withdrawn
Other recruiting trials for Critical Illness
Currently open trials in the same condition.
- NCT06189924 — Exhaled Breath Condensate Analysis in Mechanically Ventilated Patients · recruiting
- NCT07418242 — Prognostic Value of Novel Biomarkers on Adverse Renal Outcomes in High-Risk Cardiac Surgery Patients · recruiting
- NCT07101640 — PK, Safety and Preliminary Efficacy Study of Montelukast in Critically Ill Infants With Developing Bronchopulmonary Dysp · Phase 1, PHASE2 · recruiting
- NCT07177183 — Low Serum Creatinine as a Predictor of Prolonged Mechanical Ventilation and Weaning Failure · NA · recruiting
- NCT07369258 — Clinical Application of Listening to Music to Prevent Delirium in the Intensive Care Unit · NA · recruiting
Other Göteborg University trials
Trials by the same sponsor.
- NCT07260604 — HIFEM for Incontinence After Menopause High-Intensity Focused Electromagnetic (HIFEM) · NA · not yet recruiting
- NCT07213245 — Metabolic Effects of Short-term Ultra-processed Food Intake (MEST-UPF) · NA · recruiting
- NCT07178405 — Effects of Meal Characteristics on Appetite · NA · completed
- NCT07172841 — Non-invasive Diagnostics of Shunt Obstruction in Adult Hydrocephalus · NA · not yet recruiting
- NCT07128940 — Biomarker pAtterns Reflecting habITual fOod iNtakE: the BARITONE Project · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07401420 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Göteborg University
- Last refreshed: 10 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07401420.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing